You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 興科蓉醫藥盤中漲21%“血製品+醫美”雙輪驅動戰略帶來業績彈性和成長確定性
格隆匯 02-14 16:16
格隆匯2月14日丨興科蓉醫藥盤中漲21.25%,報0.485港元;收漲12.5%,報0.45港元,總市值9.15億港元。興科蓉醫藥是國內矢藥行業領先的綜合營銷、推廣及渠道管理服務商。格隆匯近日發佈的《興科蓉醫藥(6833.HK):“血製品+醫美”並駕齊驅,業績估值共振可期》文章指出,2022年,興科蓉醫藥持續開發醫美新產品,積極拓展業績新增長點。在創新研發提速的同時,還將醫美佈局延申到下游業務,完整構建醫美全產業鏈模式。此外,作為國際四大血製品巨頭之一奧克特琺瑪的獨家代理商,興科蓉醫藥在國內血製品市場具有較強的稀缺性和競爭力。上半年,儘管受到疫情影響,興科蓉醫藥人血白蛋白注射液的批簽發量為3066萬瓶,同比增長4%;銷售額為11.27億元,同比上升40%,業務依舊實現穩定增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account